MAPT and Alzheimer disease: Currently, biomarker protein levels of amyloid β-42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) in the cerebrospinal fluid (CSF) of YOAD and LOAD patients are routinely used to confirm a diagnosis consistent with AD [16–19].